Glenmark reduces the price of FabiFlu | Fusion - WeRIndia

Last month, Glenmark Pharmaceuticals launched an antiviral drug, Favipiravir, under the brand name FabiFlu for COVID-19 patients who have mild to moderate symptoms. The drug was approved to be used under an emergency category.

Since the majority of patients have mild to moderate symptoms in India, the drug is expected to benefit several people.

FiabiFlu was priced at ₹103 per tablet initially. But, yesterday Glenmark Pharmaceuticals announced that the price of the drug has been slashed by 27 per cent to ₹75 per tablet.

The company said that the company achieved a higher yield and better scale; hence, it wants the benefit to be passed on to the patients. And that’s why the price has been reduced.

Now the company is manufacturing the active pharmaceutical ingredient (API) and formulations in India. Hence the drug is scalable with good yield.

The company says that their drug FabiFlu is sold at the lowest price in India of all such drugs in other countries.

The company hopes the drug may be accessible to more patients now due to price reduction.

Glenmark also inaugurated postmarketing surveillance (PMS) study to monitor the safety and efficiency of the drug in patients.

FabiFlu is the first Favipiravir-approved medication in the country to be used for COVID-19 patients who have mild to moderate symptoms.

The company said that it completed phase 3 clinical trials with this drug in COVID-19 patients who have mild to moderate symptoms in the country. And the results will be available soon.

The company is also testing another antiviral drug. Now, phase 3 clinical trials are going on for this drug in India.

The drug is a combination of Favipiravir and Umifenovir to be used for moderate hospitalised adults.

Photo by PIXNIO public domain (CC0)

Image Reference: https://pixnio.com/science/medical-science/doctor-laboratorymedical-medicine-chemistry-test-tube-science